Their tolerogenic activity was observed in the model of experimental colitis, inflammatory bowel disease and in experimental autoimmune encephalitis (EAE) [67], suggesting that targeting CD8+CD28- Tregs or their depletion may represent a potential strategy to enhance antitumor immunity in cancer. This evidence concerns the gene CD8A and colitis.